[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"age-related-hearing-loss\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:age-related-hearing-loss":29},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,8,0,[8,43,75,102,126,152,175,200],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":13,"acronym":14,"eligibilityCriteria":15,"healthyVolunteers":16,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":19,"targetDuration":4,"studyType":22,"phases":23,"briefSummary":25,"conditions":26,"keywords":4,"overallStatus":31,"whyStopped":4,"lastUpdateSubmitDate":32,"lastUpdatePostDateStruct":33,"startDateStruct":36,"completionDateStruct":38,"leadSponsor":40,"locationsCount":4},"100053950","hears-maryland-extending-capacity-for-affordable-accessible-hearing-care-through-older-adult-peer-mentorship-100053950",false,"NCT07699146","HEARS Maryland: Extending Capacity for Affordable, Accessible Hearing Care Through Older Adult Peer Mentorship","HEARS MD","Inclusion Criteria:\n\n* Age 60 years or older\n* English-speaking\n* Aural-oral verbal communication as primary communication modality\n* Post-lingual hearing loss (Audiometric pure tone averages \\[0.5-2kHz\\] in better ear \\>25 dB)\n\nExclusion Criteria:\n\n* Current self-reported use of hearing aid or amplification device\n* Medical contraindication to use hearing aids (e.g. draining ears)",true,"ALL","60 Years",{"count":20,"type":21},300,"ESTIMATED","INTERVENTIONAL",[24],"NA","This study aims to assess the effectiveness of a Community Health Worker (CHW) delivered hearing loss intervention program (HEARS) for older adults in Maryland in collaboration with community organizations.",[27,28,29,30],"Hearing Loss","Hearing Impairment","Age Related Hearing Loss","Age-related Hearing Impairment","NOT_YET_RECRUITING","2026-07-07",{"date":34,"type":35},"2026-07-13","ACTUAL",{"date":37,"type":21},"2026-11",{"date":39,"type":21},"2029-12",{"name":41,"class":42},"Johns Hopkins University","OTHER",{"id":44,"slug":45,"hasResults":11,"nctId":46,"briefTitle":47,"officialTitle":48,"acronym":49,"eligibilityCriteria":50,"healthyVolunteers":11,"sex":17,"minAge":51,"maxAge":52,"enrollmentInfo":53,"targetDuration":4,"studyType":22,"phases":55,"briefSummary":57,"conditions":58,"keywords":60,"overallStatus":63,"whyStopped":4,"lastUpdateSubmitDate":64,"lastUpdatePostDateStruct":65,"startDateStruct":67,"completionDateStruct":69,"leadSponsor":71,"locationsCount":74},"100643036","phase-2-first-clinical-study-to-evaluate-safety-tolerability--pk-of-dx243-in-healthy-volunteers-and-patients-with-hearing-loss-100643036","NCT07637981","First Clinical Study to Evaluate Safety, Tolerability & PK of DX243 in Healthy Volunteers and Patients With Hearing Loss","Double-blind, Randomised, Placebo-controlled Phase 1\u002F2a Study of Safety, Tolerability and PK of Single and Repeated SC Doses of DX243 in Healthy Volunteers, and 1-month Safety and Efficacy in Moderately Severe Age-related Hearing Loss","DX243-101","Inclusion Criteria:\n\n* Patient having self-reported recent difficulty hearing in noisy environments for at least 6 months prior to screening.\n* Patient exhibiting a speech-in-noise hearing deficit in at least one ear;\n* Patient having audiometrically-defined normal hearing or up to moderately severe hearing impairment\n\nExclusion Criteria:\n\n* Current tympanic membrane perforation;\n* Current acute or chronic otitis;\n* Genetic hearing loss;\n* Symmetric or asymmetric severe hearing loss;\n* Any therapy known as ototoxic;\n* Acute chronic otitis media or otitis externa terminated less than 7 days prior to randomisation;\n* History of chronic inflammatory or suppurative ear disease or cholesteatoma;\n* History of otosclerosis, suspected perilymph fistula or membrane rupture, suspected retro-cochlear lesion, barotrauma;\n* Prior ear surgery of any kind;\n* Fluctuating hearing loss;\n* Patient with conductive hearing loss;\n* History of Meniere's disease, autoimmune hearing loss, radiation-induced hearing loss, acoustic neuroma","18 Years","75 Years",{"count":54,"type":21},24,[56],"PHASE2","Phase 2a: Multiple Ascending Dose (MAD) in male and female patients with hearing loss:\n\nThe study will be conducted according to a randomised, placebo-controlled, double-blind design. A total of 24 patients, otherwise healthy, aged up to 75 years old, with mild to moderate hearing loss will be included. Two cohorts of 12 male or female patients (no ratio is required) will receive two different flat doses (low dose and high dose) ofDX243 or placebo for 29 days using SC administration. In each cohort of 12 patients, 4 will be randomised to placebo and 8 to DX243, so at the end of Phase 2a, 8 patients will have received placebo, 8 the low dose and 8 the high dose of DX243.\n\nThe primary objective is to evaluate the safety and tolerability of DX243 administered subcutaneously after repeated doses. The secondary objectives are to detect preliminary signal of efficacy, using speech in noise tests, tonal and vocal audiometry, as well as tinnitus and quality of life.",[59],"Age-related Hearing Loss",[61,62],"Age-related hearing loss","DX243","RECRUITING","2026-06-04",{"date":66,"type":35},"2026-06-10",{"date":68,"type":35},"2026-05-13",{"date":70,"type":21},"2027-10",{"name":72,"class":73},"Dendrogenix","INDUSTRY",1,{"id":76,"slug":77,"hasResults":11,"nctId":78,"briefTitle":79,"officialTitle":79,"acronym":4,"eligibilityCriteria":80,"healthyVolunteers":16,"sex":17,"minAge":18,"maxAge":81,"enrollmentInfo":82,"targetDuration":84,"studyType":85,"phases":4,"briefSummary":86,"conditions":87,"keywords":88,"overallStatus":31,"whyStopped":4,"lastUpdateSubmitDate":93,"lastUpdatePostDateStruct":94,"startDateStruct":96,"completionDateStruct":98,"leadSponsor":100,"locationsCount":4},"100637745","prediction-of-age-related-hearing-loss-based-on-comprehensive-risk-factors-100637745","NCT07612618","Prediction of Age-Related Hearing Loss Based on Comprehensive Risk Factors","Inclusion Criteria:\n\n1. Age ≥ 60 years;\n2. Availability of longitudinal pure-tone audiometry data;\n3. Documented history of occupational noise exposure;\n4. Complete clinical data (including past medical history and medication history).\n\nExclusion Criteria:\n\n1. Hearing loss caused by non-age or non-noise factors (e.g., otitis media, otosclerosis, Meniere's disease);\n2. Missing clinical data \\>20%;\n3. Concurrent severe mental illness or cognitive impairment (unable to complete audiological assessment).","100 Years",{"count":83,"type":21},1000,"1 Year","OBSERVATIONAL","This study aims to develop a predictive model for age-related hearing loss (ARHL) based on multi-source risk factors and artificial intelligence techniques. A retrospective analysis will be conducted on 1,000 cases with 15-year longitudinal clinical data, including audiological assessments and noise exposure history. Machine learning algorithms will be employed to construct a predictive model for hearing loss progression. Additionally, a prospective cohort of 100 community-dwelling elderly individuals will be enrolled. Blood samples will be collected for low-abundance targeted proteomics analysis to screen for biomarkers associated with cognitive impairment. This study will establish an early risk identification tool for ARHL and propose strategies for the screening and prevention of dementia in individuals with hearing impairment, thereby providing evidence-based support for early intervention in auditory and cognitive health in the elderly.",[59],[61,89,90,91,92],"prediction model","machine learning","proteomics","cognitive impairment","2026-05-21",{"date":95,"type":35},"2026-05-29",{"date":97,"type":21},"2026-06-01",{"date":99,"type":21},"2027-12-31",{"name":101,"class":42},"Chinese PLA General Hospital",{"id":103,"slug":104,"hasResults":11,"nctId":105,"briefTitle":106,"officialTitle":106,"acronym":107,"eligibilityCriteria":108,"healthyVolunteers":16,"sex":17,"minAge":51,"maxAge":4,"enrollmentInfo":109,"targetDuration":4,"studyType":85,"phases":4,"briefSummary":111,"conditions":112,"keywords":114,"overallStatus":31,"whyStopped":4,"lastUpdateSubmitDate":118,"lastUpdatePostDateStruct":119,"startDateStruct":121,"completionDateStruct":123,"leadSponsor":125,"locationsCount":74},"100638611","management-of-age-related-auditory-decline-and-early-warning-of-its-co-occurring-dementia-100638611","NCT07608640","Management of Age-Related Auditory Decline and Early Warning of Its Co-occurring Dementia","AHEAD","Inclusion Criteria:\n\n1. Aged 60 years or older.\n2. Clear consciousness and able to cooperate with all study assessments and examinations.\n3. Permanent local residents who have lived in the area for at least 9 months per year and are willing to complete long-term follow-up.\n\nlong-term follow-up：\n\n1. Diagnosis of sensorineural hearing loss.\n2. Bilaterally symmetric hearing with air conduction threshold difference ≤15 dB at 0.5 kHz, 1 kHz, 2 kHz and 4 kHz between two ears.\n3. Hearing loss not caused by non-age-related factors.\n\nExclusion Criteria:\n\n1. Unable to complete pure-tone audiometry and other auditory examinations. History of central nervous system diseases, including Parkinson's disease, stroke, intracranial tumor or brain trauma.\n2. Severe uncontrolled systemic diseases (cardiac, pulmonary, hepatic, renal insufficiency) or advanced malignant tumor with expected survival less than 3 years.\n3. Any other condition judged by the investigator inappropriate for study enrollment.",{"count":110,"type":21},3000,"Against the backdrop of global population aging, age-related hearing loss (ARHL) has reached epidemic proportions and is increasingly recognized as an independent risk factor for cognitive decline and other major neurodegenerative diseases. This study aims to systematically develop an integrated framework for the early warning, precise assessment, and intervention management of ARHL.\n\nUsing a national multicenter design, the project will establish a prospective cohort of more than 3,000 older adults. We will integrate multimodal data including audiological tests, cognitive function assessments, and blood biomarkers, and employ artificial intelligence and unsupervised machine learning methods to address critical bottlenecks in the field: the unclear mechanistic link between ARHL and cognitive decline, and the lack of validated predictive tools.\n\nSpecifically, this study will: (1) develop data-driven clinical classification criteria for ARHL; (2) create a personalized \"Hearing Health Clock\" predictive model; (3) identify minimally invasive blood biomarkers for early detection of cognitive impairment; and (4) formulate a multidimensional early dementia screening program suitable for community-wide implementation. The findings will provide scientific evidence and practical tools for the prevention and control of hearing and cognitive health risks in older adults in China.",[59,113],"Dementia",[113,27,115,116,117],"Disease Burden","Cohort Study","Predictive Model","2026-05-20",{"date":120,"type":35},"2026-05-27",{"date":122,"type":21},"2026-05-25",{"date":124,"type":21},"2028-12-31",{"name":101,"class":42},{"id":127,"slug":128,"hasResults":11,"nctId":129,"briefTitle":130,"officialTitle":131,"acronym":4,"eligibilityCriteria":132,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":133,"enrollmentInfo":134,"targetDuration":4,"studyType":22,"phases":136,"briefSummary":137,"conditions":138,"keywords":140,"overallStatus":63,"whyStopped":4,"lastUpdateSubmitDate":143,"lastUpdatePostDateStruct":144,"startDateStruct":146,"completionDateStruct":148,"leadSponsor":150,"locationsCount":74},"100583942","comparing-the-efficacy-of-domestic-versus-imported-hearing-aids-in-arhl-100583942","NCT06882889","Comparing the Efficacy of Domestic Versus Imported Hearing Aids in ARHL","A Non-Inferiority, Single-Blind, Randomized Controlled Trial Comparing the Efficacy of Domestic Versus Imported Hearing Aids in Patients With Moderate to Severe and Severe Age-Related Hearing Loss","Inclusion Criteria:\n\n1. Age ≥ 60 years and ≤ 85 years;\n2. Diagnosed with age-related hearing Loss, which is characterized by bilateral, symmetrical, and gradually progressive hearing loss primarily affecting high frequencies, along with a decline in speech recognition ability, as referenced in the \"Expert Consensus on Diagnosis and Intervention of Age-Related Hearing Loss\" (2019 edition);\n3. Age-related hearing Loss is of moderate to severe or severe sensorineural hearing loss, with moderate to severe defined as 50 to \\\u003C65 dB HL, and severe defined as 65 to \\\u003C80 dB HL;\n4. Chinese nationality, able to complete all assessments in the Chinese language;\n5. Right-handed;\n6. No significant neurological diseases, severe systemic diseases, family history of genetic disorders, or major psychiatric conditions;\n\nExclusion Criteria:\n\n1. Exclusion of noise-induced hearing loss, hereditary hearing loss, drug-induced hearing loss, etc.;\n2. Inability to use hearing aids ;\n3. Presence of dementia, Parkinson's disease, or other neurodegenerative diseases that may affect study compliance;\n4. History of cerebrovascular accidents, stroke, epilepsy, or other central nervous system disorders;\n5. Other conditions deemed by the investigator to be exclusionary.","85 Years",{"count":135,"type":21},80,[24],"This study compares the hearing improvement effects of domestic hearing aids and imported hearing aids in 80 patients with moderate to severe and severe age-related hearing loss. Patients will be randomly assigned to either the experimental group (domestic hearing aids) or the control group (imported hearing aids) and will undergo a 30-minute trial. Pure Tone Average (PTA) and Speech Recognition Threshold (SRT) will be measured both before and after the trial. The improvements in PTA and SRT will be calculated.The market prices of the hearing aids and the degree of hearing improvement in decibels will be recorded. These data will be used to conduct a comprehensive cost-effectiveness analysis. After the trial, the International Outcome Inventory for Hearing Aids (IOI-HA) and the Abbreviated Profile of Hearing Aid Benefit (APHAB) will be used to assess the benefits of the hearing aids.",[59,139],"Hearing Loss, Sensorineural",[61,141,142],"Hearing Aids","Randomized Controlled Trial","2025-08-12",{"date":145,"type":35},"2025-08-13",{"date":147,"type":35},"2024-10-24",{"date":149,"type":21},"2025-12-31",{"name":151,"class":42},"Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University",{"id":153,"slug":154,"hasResults":11,"nctId":155,"briefTitle":156,"officialTitle":157,"acronym":4,"eligibilityCriteria":158,"healthyVolunteers":11,"sex":17,"minAge":159,"maxAge":52,"enrollmentInfo":160,"targetDuration":4,"studyType":22,"phases":162,"briefSummary":163,"conditions":164,"keywords":4,"overallStatus":31,"whyStopped":4,"lastUpdateSubmitDate":166,"lastUpdatePostDateStruct":167,"startDateStruct":169,"completionDateStruct":171,"leadSponsor":173,"locationsCount":74},"100593923","a-clinical-trial-of-the-safety-and-efficacy-of-tj0113-capsules-in-the-treatment-of-patients-with-age-related-hearing-loss-100593923","NCT07012746","A Clinical Trial of the Safety and Efficacy of TJ0113 Capsules in the Treatment of Patients With Age-related Hearing Loss","A Randomized, Double-Blind, Placebo-Parallel-Controlled Clinical Trial to Explore the Safety and Efficacy of TJ0113 Capsules in the Treatment of Patients With Age-related Hearing Loss","Inclusion Criteria:\n\n1. The subjects voluntarily participate in the clinical trial, sign the informed consent form, understand and follow the protocol, and fully understand the test content, process and possible adverse reactions.\n2. Age between 65 and 80 years (including the critical value)\n3. A diagnosis of symmetrical sensorineural deafness (SNHL) with a history of\\> 3 months (binaural threshold difference in mean PTA frequency \\\u003C15 dB HL), the PTA level should be between moderate (\\> 35dB) and severe (\\\u003C80dB) hearing loss\n4. Hearing aids have not been used, or otherwise, it should be used regularly for more than 3 years and stopped for 3 months before enrollment.\n5. Subjects and their partners had no birth plan, sperm or egg donation plans from the screening period until within 6 months after the end of the trial and would voluntarily take effective contraception (e. g. abstinence, condoms, etc.). Male subjects should agree to avoid sperm donation within 6 months from the start of administration until cessation of study treatment. Female subjects should be menopausal (over 24 months).\n\nExclusion Criteria:\n\n1. The presence of implants in the study ear (such as cochlear implant, artificial hearing bone, etc.);\n2. Suffering from acute otitis media or other ear infection within the previous 3 months or previous chronic suppurative otitis media or tympanic membrane perforation, or with conductive deafness, previous history of ear trauma or surgery, combined middle ear or inner ear malformation, otosclerosis, Meniere's disease, sudden deafness and no recovery of hearing, all of which will impact results explained.\n3. Patients with sensorineural deafness caused by non-aging factors (e. g., hereditary deafness, congenital deafness, drug-induced deafness, noise deafness, neurosyphilis, severe retrocochlear lesions or organic lesions), and unilateral deafness\n4. Occupation that is sensitive to sound: musician, conductor, music teacher, etc.\n5. Use headphones at high volume or frequent exposure to noise in previous work or life;\n6. History of alcohol or drug dependence \u002F drug abuse in the last 1 year;\n7. Positive pregnancy test at screening or at the baseline visit, pregnant, lactating, or planned to become pregnant during the trial\n\n7.Failure to swallow oral medication, or, according to the investigator, any conditions that may significantly affect the absorption, distribution, metabolism and excretion of the drug, or that may pose a hazard to the subjects participating in this trial; 9.People who currently taking drugs that can improve symptoms such as dementia and depression 10.Subjects with a severe or unstable systemic disease, such as serious congenital disease, blood disease, endocrine disease, nerve or nervous system disease, end-stage disease, head and neck tumor radiotherapy and chemotherapy history, major surgical treatment, psychological disorders (severe insomnia, severe depression, severe anxiety, etc. diagnosed within the previous 90 days ) or history and clinical significance of abnormal baseline laboratory values, such as hepatic insufficiency (alanine transaminase (ALT) and \u002F or alanine transaminase (AST) is 2 times above the upper limit of the reference range, or renal insufficiency (creatinine clearance Ccr \\\u003C30 mL\u002Fmin), or history of malignant tumors and the detection results of tumor markers during the screening period have clinical significance, or unsuitable participants, as judged by the investigator; 11.Subjects suffering from any one of the following heart diseases: a. having uncontrolled or serious cardiovascular and cerebrovascular disease, including the development of grade II ( New York Heart Association, NYHA) or above congestive heart failure, unstable angina, acute myocardial infarction within 6 months before the first drug administration, or cardiac arrhythmias requiring treatment at screening; With b. hypertension (systolic pressure≥ 160mmHg and \u002F or diastolic v≥ 100mmHg), and after the combination of two or more antihypertensive drugs can not be reduced to the normal range; or c.with a history of clinically significant ECG abnormalities, the QRS time was\\> 120ms, Long QT syndrome: QTc interval\\> 450ms in male or QTc interval\\> 470ms in female.\n\n12.Participated in a clinical study involving the administration, device, or surgery of the study drug (new chemical entity) within 90 days or 5 half-lives (whichever is longer) 13.Patients with a previous history of hepatitis B, or any of the following indicators are positive at screening: hepatitis B virus surface antigen (HBsAg), hepatitis C virus (HCV) antibody, human immunodeficiency virus (HIV) antibody, or treponema pallidum antibody.\n\n14.The subject is not fit to participate in the study if the investigator considers. Or the subject could not participate in the trial for his own reasons, or the behavior subject may interfere with treatment, study or interpretation of results (e. g., previous treatment with high-dose aminoglycosides).","65 Years",{"count":161,"type":21},60,[24],"The purpose of this study is to explore the safety and efficacy of TJ0113 capsules in patients with age-related hearing loss.",[29,165],"Deafness","2025-06-01",{"date":168,"type":35},"2025-06-10",{"date":170,"type":21},"2025-06-07",{"date":172,"type":21},"2027-04",{"name":174,"class":42},"Yilai Shu",{"id":176,"slug":177,"hasResults":11,"nctId":178,"briefTitle":179,"officialTitle":179,"acronym":4,"eligibilityCriteria":180,"healthyVolunteers":11,"sex":17,"minAge":159,"maxAge":181,"enrollmentInfo":182,"targetDuration":4,"studyType":22,"phases":184,"briefSummary":185,"conditions":186,"keywords":187,"overallStatus":31,"whyStopped":4,"lastUpdateSubmitDate":191,"lastUpdatePostDateStruct":192,"startDateStruct":194,"completionDateStruct":196,"leadSponsor":198,"locationsCount":4},"100583593","increasing-physical-activity-with-a-social-robot-assisted-exercise-intervention-in-older-adults-with-hearing-loss-a-feasibility-and-pilot-randomized-controlled-trial-100583593","NCT06878339","Increasing Physical Activity with a Social Robot-assisted Exercise Intervention in Older Adults with Hearing Loss: a Feasibility and Pilot Randomized Controlled Trial","Inclusion Criteria:\n\n1. ethnic Chinese aged ≥65 years old living at home;\n2. with mild to moderate HL with a pure-tone average of 20 to 50 dB across octave frequencies 0.5 to 4kHz in both ears;\n3. no cognitive impairment \\[score of ≦2 on the 5-item Abbreviated Memory Inventory for the Chinese (AMIC)\\]; and\n4. informed consent to participate in this study. Loneliness is not a pre-requisite for taking part in the research. Nevertheless, previous findings from a longitudinal cohort study indicate that approximately 46.6% of older adults with hearing loss reported feeling lonely.\n\nExclusion Criteria:\n\n1. those with a diagnosis of a major neurocognitive disorder;\n2. a history of symptomatic stroke or other disease of the central nervous system;\n3. a serious medical or psychiatric illness (e.g., severe depression, schizophrenia, bi-polar disorder) or a visual impairment that would interfere with using a robot or using hearing aids and hearing assistive technologies;\n4. have limited access to electricity at home.","90 Years",{"count":183,"type":21},40,[24],"Objectives To assess the feasibility and acceptability of using a home-based, social robot-assisted intervention (SRAI) for older adults with hearing loss (HL), and to examine the preliminary effects of SRAI on improving physical activity, loneliness, communication, and health-related quality of life in this population.\n\nHypothesis to be tested SRAI is feasible for implementation at home and acceptable to participants. Upon completing the 10-week intervention and the 1-month follow-up, the intervention group (IG) will report significantly greater improvements in measured outcomes. These findings will support subsequent investigations in a larger-scale randomized controlled trial (RCT).\n\nDesign and subjects A two-arm, single-blinded, pilot RCT with individual semi-structured interviews. Chinese adults aged 65 years or older, with mild-to-moderate HL with a pure-tone average of 20-50 dB across octave frequencies 0.5 to 4kHz in both ears.\n\nStudy instruments This study will feature a 2 kg, 30 cm tall and 20 cm wide, Cantonese-speaking humanoid social robot named KaKa.\n\nInterventions Each IG participant will receive SRAI at home for 10 weeks. This will include auditory rehabilitation and 60 min\u002Fday, 3 days\u002Fweek of varied multicomponent physical activity following the World Health Organization's evidence-based recommendations. The control group will engage in physical activity at the same intensity level and frequency as the IG without a robot.\n\nMain outcome measures Physical activity levels.\n\nData analysis Descriptive statistics, an independent sample t-test or chi square test, generalized estimating equation and thematic analysis will be used.\n\nExpected results Participants could benefit from incorporating tailored intervention for physical activity with auditory rehabilitation.",[59],[188,189,190],"age-related hearing loss","physical activity","health-related quality of life","2025-03-11",{"date":193,"type":35},"2025-03-14",{"date":195,"type":21},"2025-05",{"date":197,"type":21},"2027-03",{"name":199,"class":42},"The Hong Kong Polytechnic University",{"id":201,"slug":202,"hasResults":11,"nctId":203,"briefTitle":204,"officialTitle":204,"acronym":4,"eligibilityCriteria":205,"healthyVolunteers":16,"sex":17,"minAge":18,"maxAge":133,"enrollmentInfo":206,"targetDuration":4,"studyType":22,"phases":208,"briefSummary":209,"conditions":210,"keywords":4,"overallStatus":63,"whyStopped":4,"lastUpdateSubmitDate":213,"lastUpdatePostDateStruct":214,"startDateStruct":216,"completionDateStruct":218,"leadSponsor":220,"locationsCount":74},"100492584","a-prospective-cohort-study-on-change-of-cognitive-function-in-aged-related-hearing-loss-with-hearing-aids-100492584","NCT05694039","A Prospective Cohort Study On Change of Cognitive Function In Aged-related Hearing Loss With Hearing Aids","Inclusion Criteria:\n\nAge\\>60yrs，≤85yrs（MCI prevalence was 6.7% for ages 60-64, 8.4% for 65-69, 10.1% for 70-74, 14.8% for 75-79,and25.2% for80-84）; Sensorineural Hearing loss with pure-tone thresholds 25-70 dB HL at octave frequencies between 250 and 4000 Hz, 4 frequency PTA of ≥ 30 dB HL, and the PTA ≤ 90 dB HL; Diagnosed as Presbycusis; Score of 23 or below on Mini-Mental Status Exam (MMSE); Score of 22 or below on Montreal Cognitive Assessment (MoCA);\n\nExclusion Criteria:\n\nHearing loss exceeding the limits that can be successfully aided with hearing aids (i.e., profound hearing loss); Significant history of otologic or neurologic disorders; Hearing loss remediated with a cochlear implant (cannot wear hearing aids); Any clinically significant unstable or progressive medical condition; Any condition which, in the opinion of the investigator, places the participant at unacceptable risk if he or she were to participate in the study.",{"count":207,"type":21},388,[24],"Background:\n\nDeafness is one of the nine potentially modifiable risk factors for dementia simulated by the Lancet dementia Prevention, intervention and Care Committee in 2017. Some studies have found that the risk factors of dementia in deafness system, with the increase of the degree of deafness, the risk of cognitive decline increases, while after long-term wear of hearing aids, the deterioration of immediate and delayed memory is less, and the possibility of cognitive decline slows down. Therefore, it is necessary for us to improve the auditory ability of patients with deafness through auditory intervention, so as to slow down its effect on dementia and reduce the incidence of dementia. At present, auditory intervention methods include hearing aid wearing and cochlear implant.\n\nHowever, there are few studies on cognitive function of presbycusis patients in China, and there is no research on how many years of auditory intervention can effectively slow down the incidence of dementia in presbycusis patients with MCI. Therefore, we intend to conduct a prospective cohort study on the changes of cognitive function of presbycusis under hearing aid intervention.",[59,139,211,212],"Hearing Aid","Cognitive Function Abnormal","2023-01-20",{"date":215,"type":35},"2023-01-23",{"date":217,"type":35},"2022-03-09",{"date":219,"type":21},"2028-03-09",{"name":151,"class":42}]